Memantina Doc Generici

Memantine, the active ingredient in Memantina Doc Generici, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is used to treat moderate to severe Alzheimer’s disease and related dementia in adult patients.

GNH USA supplies Memantina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is indicated for neurodegenerative conditions where excessive NMDA receptor activity contributes to cognitive decline.

Alzheimer's disease (moderate to severe): improves cognition and daily functioning in patients with advanced disease. Moderate to severe dementia of Alzheimer’s type: may slow functional deterioration. Behavioral disturbances in Alzheimer’s disease: can reduce agitation and improve patient cooperation.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Constipation - Nausea - Fatigue - Confusion

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or severe skin reactions - Seizures - Hepatic injury - Cardiac arrhythmias - Suicidal thoughts or behavior - Severe allergic reactions (anaphylaxis)

Memantine should be used with caution in specific clinical situations.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic impairment: monitor liver enzymes and consider dose modification. History of seizures: use cautiously as the drug may lower seizure threshold. Concomitant NMDA antagonists: avoid combined use to reduce risk of additive CNS effects. Pregnancy and breastfeeding: safety not established; weigh potential benefits against unknown risks. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Memantine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can exacerbate central nervous system depression. - Other NMDA antagonists (e.g., dextromethorphan): heightened risk of adverse CNS effects. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - Diuretics: increased risk of dizziness or orthostatic hypotension.